Showing results (11-20 of 86) with videos related to
Sort By:
Pageof 9
Current Opinion in Virology|August 7, 2016
Oncolytic herpes simplex virus interactions with the host immune systemDipongkor Saha, Hiroaki Wakimoto, Samuel D RabkinCancer Research|March 1, 2005
Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic miceRenbin Liu, Susan Varghese, Samuel D RabkinDrugs of the Future|February 9, 2016
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMADipongkor Saha, Seemin S Ahmed, Samuel D RabkinJournal for Immunotherapy of Cancer|May 28, 2020
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastomaDipongkor Saha, Samuel D Rabkin, Robert L MartuzaCancer Cell|August 16, 2017
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint BlockadeDipongkor Saha, Robert L Martuza, Samuel D RabkinFrontiers in Cellular and Infection Microbiology|June 16, 2023
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsKimia Kardani, Judit Sanchez Gil, Samuel D RabkinCancer Research|January 20, 2007
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptideManish Aghi, Samuel D Rabkin, Robert L MartuzaCancer Research|October 19, 2006
Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vectorToshihiko Kuroda, Samuel D Rabkin, Robert L MartuzaImmunotherapy|July 17, 2018
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastomaDipongkor Saha, Robert L Martuza, Samuel D RabkinNeurosurgical Focus|July 7, 2007
Oncolytic herpes simplex virus therapy for peripheral nerve tumorsDeva S Jeyaretna, Samuel D Rabkin, Robert L MartuzaPageof 9